From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

Abatacept for prophylaxis of acute graft-vs-host disease

Last Updated: Monday, May 16, 2022

The Food and Drug Administration recently approved abatacept, a selective T-cell costimulation modulator, for prophylaxis of acute GvHD in combination with a calcineurin inhibitor, such as cyclosporine or tacrolimus, and methotrexate in adult and pediatric patients undergoing hematopoietic stem cell transplantation.

The ASCO Post
Advertisement
News & Literature Highlights
Advertisement
Advertisement